Table 1.
Categorization of albuminuria and renal outcomes in the cardiovascular RCTs
| EMPA-REG OUTCOME | CANVAS | DECLARE-TIMI 58 | VERTIS CV | |
|---|---|---|---|---|
| (n = 6953; | (n = 10 033; | (n = 16 842; | (n = 8246; | |
| Criteria | Empagliflozin) | Canagliflozin) | Dapagliflozin) | Ertugliflozin) |
| Baseline albuminuria, n (%) | ||||
| A1 (<30 mg/g) | 4171 (60.0) | 7007 (69.8) | 11 644 (69.1) | 4783 (59.6) |
| A2 (30–300 mg/g) | 2013 (29.0) | 2266 (22.6) | 4029 (23.9) | 2492 (31.0) |
| A3 (>300 mg/g) | 769 (11.1) | 760 (7.6) | 1169 (6.9) | 755 (9.4) |
| Renal outcomes | ||||
| HR (95% CI) | ||||
| Composite renal outcome | 0.54 (0.40–0.75) | 0.53 (0.33–0.84) | 0.53 (0.43–0.66) | 0.81 (0.63–1.04) |
| creat ×2 or | creat ×2 | creat ×2 | −40% | creat ×2 |
| −40% | 0.56 (0.39–0.79) | 0.50 (0.30–0.84) −40% 0.60 (0.47–0.78) | 0.54 (0.43–0.57) | 0.64 (0.40–1.01) −40% 0.65 (0.49–0.87) |
| Need for RRT | 0.45 (0.21–0.97) | 0.77 (0.30–1.97) | 0.31 (0.13–0.79) | 0.96 (0.50–1.83) |
HR, hazard ratio; CI, confidence interval; RRT, renal replacement therapy. creat ×2, doubling of the serum creatinine; NA, not available; −40%, decrease ≥40% in eGFR.